Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in multidistrict litigation against drug makers and others over their alleged role in the opioid crisis. The company said 47 state and territorial attorneys general support the agreement, in which its specialty generics subsidiaries would file for Chapter 11 bankruptcy. Under the proposed settlement, subject to court approval and other conditions, Mallinckrodt would pay $1.6 billion in structured payments after the subsidiaries emerged from Chapter 11, the majority going to a trust that would in part cover the costs of opioid addiction treatment and related efforts, the company said.   

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 89 organizations, including hospitals, $1 million each to combat opioid and other substance…
Headline
The Substance Abuse and Mental Health Services Administration’s Office of Behavioral Health Equity recently published a report on the opioid crisis’ impact on…
Headline
The Food and Drug Administration yesterday required updated labeling for opioid pain medicine and medicine to treat opioid use disorder to recommend that…
Headline
Drug overdose deaths in the United States rose 4.6% in 2019 to 70,980, including 50,042 involving opioids, according to preliminary data released yesterday by…
Chairperson's File
COVID-19 has been at the forefront for health care professionals, and for everyone, this year. And it looks like it will remain that way for some time. However…
Headline
Suicide deaths increased by 37% between 2000 and 2018, with 41 states experiencing statistically significant increases over the same period, according to a…